原發性膽管癌治療市場：依藥物類別、給藥途徑、通路及地區分類。

Primary Biliary Cirrhosis Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年原發性膽管病性肝硬化治療市場規模估計為14.4億美元，預計2033年將達22.3億美元。預計2026年至2033年，該市場將以6.5%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	14.4億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	6.50%	2033年市場規模預測：	22.3億美元

全球原發性膽汁性肝硬化治療市場涵蓋多種藥物類別，包括熊去氧膽酸、奧貝膽酸和貝特類藥物，這些藥物可用於口服和腸外等多種給藥途徑。醫院和零售藥局對這些藥物的需求，以及對更有效率、更可靠解決方案的需求，是推動市場成長的主要因素。持續的技術進步和不斷成長的終端用戶需求，正在推動該市場的發展。

市場動態：

口服和注射劑型的廣泛應用、終端用戶需求的成長以及對提高療效和性能的持續關注，預計將成為全球原發性膽汁性肝硬化治療市場成長的主要驅動力。更多樣化的選擇也使得更多使用者能夠獲得這些治療方案。

例如，各公司正在拓展產品系列，以滿足醫院藥局和零售藥局不斷變化的需求。此外，預計在預測期內，加大對創新和新技術整合的投資將為市場參與者創造新的成長機會。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據公司概況、產品系列、主要亮點、財務績效和策略等參數，介紹了全球原發性膽汁性肝硬化治療市場主要參與者的概況。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球原發性膽汁性肝硬化治療市場」報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球原發性膽汁性肝硬化治療市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 比荷盧經濟聯盟
- 丹麥
- 挪威
- 瑞典
- 其他歐洲國家
亞太地區
- 中國
- 台灣
- 印度
- 日本
- 印尼
- 馬來西亞
- 菲律賓
- 新加坡
- 澳洲
- 韓國
- 其他亞太國家
中東和非洲
巴林
科威特
阿曼
卡達
沙烏地阿拉伯
UAE
以色列
南非
北非
中非
其他中東國家

第1章競爭情勢

AbbVie Inc.
Takeda Pharmaceutical Company Ltd.
Intercept Pharmaceuticals Inc.
Gilead Sciences, Inc.
Novartis AG
Pfizer Inc.
Sanofi SA
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Cipla Ltd.
Sun Pharmaceutical Industries Ltd.
Dr. Reddy's Laboratories Ltd.

第2章

調查方法
關於本公司

簡介目錄

Product Code: CMI1539

Primary Biliary Cirrhosis Drugs Market is estimated to be valued at USD 1.44 billion in 2026 and is expected to reach USD 2.23 billion by 2033, growing at a compound annual growth rate (CAGR) of 6.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1.44 billion
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	6.50%	2033 Value Projection:	USD 2.23 billion

The global primary biliary cirrhosis drugs market covers a broad set of drug class categories, including Ursodeoxycholic Acid, Obeticholic Acid, and Fibrates, used across applications such as Oral, and Parenteral. Demand is supported by adoption among Hospital Pharmacies, and Retail Pharmacies and the need for more efficient, reliable solutions. Continued technological advancement and rising end-user requirements are shaping the growth of this market.

Market Dynamics:

Growing adoption across Oral, and Parenteral, rising end-user demand, and a continued focus on improving efficiency and performance are major factors expected to drive growth of the global primary biliary cirrhosis drugs market. A wider range of available options is making these solutions accessible to a broader base of users.

For instance, companies are expanding their portfolios to address evolving requirements across Hospital Pharmacies, and Retail Pharmacies. Moreover, increasing investment in innovation and new technology integration is expected to create new growth opportunities for market players over the forecast period.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global primary biliary cirrhosis drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Ltd., Intercept Pharmaceuticals Inc., Gilead Sciences, Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Merck & Co, Inc., Mitsubishi Tanabe Pharma Corporation, Cipla Ltd., Sun Pharmaceutical Industries Ltd., and Dr. Reddys Laboratories Ltd, among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global primary biliary cirrhosis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary biliary cirrhosis drugs market.

Detailed Segmentation:

Global Primary Biliary Cirrhosis Drugs Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
Ursodeoxycholic Acid
Obeticholic Acid
Fibrates
Immunosuppressants
Others
Global Primary Biliary Cirrhosis Drugs Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
Oral
Parenteral
Others
Global Primary Biliary Cirrhosis Drugs Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles:
AbbVie Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
Takeda Pharmaceutical Company Ltd.
Intercept Pharmaceuticals Inc.
Gilead Sciences, Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Merck & Co, Inc.
Mitsubishi Tanabe Pharma Corporation
Cipla Ltd.
Sun Pharmaceutical Industries Ltd.
Dr. Reddys Laboratories Ltd

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Preview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaboration
Regulatory Scenario
Key Developments
PEST Analysis
Partnership Scenario
Brand and Pricing Analysis
Distributors Landscape
Porters Analysis
Technological Advancements
Key Developments
Market Trend
Future Prospective
Top Market Players by Revenue

4. Primary Biliary Cirrhosis Drugs Market By Drug Class, 2026-2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Ursodeoxycholic Acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Obeticholic Acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Fibrates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Immunosuppressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

5. Primary Biliary Cirrhosis Drugs Market By Route of Administration, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Parentral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

6. Primary Biliary Cirrhosis Drugs Market By Distribution Channel, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

7. Primary Biliary Cirrhosis Drugs Market By Region, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Benelux
  - Denmark
  - Norway
  - Sweden
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - China
  - Taiwan
  - India
  - Japan
  - Indonesia
  - Malaysia
  - Philippines
  - Singapore
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
Bahrain
Kuwait
Oman
Qatar
Saudi Arabia
UAE
Israel
South Africa
North Africa
Central Africa
Rest of the Middle East

1. Competitive Landscape

AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Takeda Pharmaceutical Company Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Intercept Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Mitsubishi Tanabe Pharma Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Cipla Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Dr. Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies